中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.014 seconds)

    ANTI-BIG-ENDOTHELIN-1 (BIG-ET-1) ANTIBODIES AND USES THEREOF
    1.
    发明申请
    ANTI-BIG-ENDOTHELIN-1 (BIG-ET-1) ANTIBODIES AND USES THEREOF 审中-公开
    抗大黄内皮素-1（BIG-ET-1）抗体及其用途

    公开(公告)号：WO2013126740A1

    公开(公告)日：2013-08-29

    申请号：PCT/US2013/027380

    申请日：2013-02-22

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： MORTON, Lori, C. ,  MACDONALD, Douglas

    IPC: C07K16/26

    CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/26 ,  C07K2317/52 ,  C07K2317/76

    Abstract: The present invention provides antibodies that bind big-endothelin-1 ("big-ET-1 " ), and methods of using same. According to certain embodiments of the invention, the antibodies specifically bind human big-ET-1 but do not bind human small-ET-1 (i.e., the active form of endothelin-1 that results from proteolytic cleavage of big-ET-1 by endothelin-converting enzyme-1 [ECE-1]). According to certain embodiments of the invention, the anti-big-ET-1 antibodies are capable of blocking cleavage of big-ET-1 by ECE-1. The antibodies of the invention are useful for the treatment of big-ET-1 -related disorders, including hypertension disorders, fibrotic disorders, neurodegenerative disorders, retinal disorders, pain and cancers.

    Abstract translation: 本发明提供了结合大内皮素-1（“大ET-1”）的抗体及其使用方法。 根据本发明的某些实施方案，抗体特异性结合人大ET-1，但不结合人小ET-1（即，由大ET-1的蛋白水解切割引起的内皮素-1的活性形式由 内皮素转化酶-1 [ECE-1]）。 根据本发明的某些实施方案，抗大ET-1抗体能够通过ECE-1阻断大ET-1的切割。 本发明的抗体可用于治疗大ET-1相关疾病，包括高血压病症，纤维化病症，神经变性疾病，视网膜疾病，疼痛和癌症。

    PEPTIDE-MHC II PROTEIN CONSTRUCTS AND USES THEREOF
    8.
    发明申请
    PEPTIDE-MHC II PROTEIN CONSTRUCTS AND USES THEREOF 审中-公开

    公开(公告)号：WO2021113297A1

    公开(公告)日：2021-06-10

    申请号：PCT/US2020/062801

    申请日：2020-12-02

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： MACDONALD, Douglas ,  BUCKLER, David

    IPC: C07K14/47 ,  A61K39/00 ,  A61K35/17 ,  A61K38/17 ,  A61K47/64 ,  C07K14/74 ,  A61P37/00

    Abstract: Compositions comprising an MHC ligand peptide covalently attached to an MHC class II molecule are provided herein. In some compositions, the MHC ligand peptide is covalently attached to the MHC class II molecule by a peptide linker, wherein the MHC ligand peptide or the peptide linker comprises a first cysteine, wherein the MHC class II a chain or a portion thereof or the MHC class II β chain or a portion thereof comprises a second cysteine, and wherein the first cysteine and the second cysteine form a disulfide bond such that the MHC ligand peptide is bound in a peptide-binding groove formed by the MHC class II a chain or the portion thereof and the MHC class II β chain or the portion thereof. Also provided are nucleic acids encoding such compositions and methods for using such compositions to elicit an immune response in a subject.

    OPTIMIZED ANTI-CD3 BISPECIFIC ANTIBODIES AND USES THEREOF
    10.
    发明申请
    OPTIMIZED ANTI-CD3 BISPECIFIC ANTIBODIES AND USES THEREOF 审中-公开
    优化的抗CD3抗体抗体及其用途

    公开(公告)号：WO2017053856A1

    公开(公告)日：2017-03-30

    申请号：PCT/US2016/053525

    申请日：2016-09-23

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： SMITH, Eric ,  HABER, Lauric ,  BABB, Robert ,  CHEN, Gang ,  MACDONALD, Douglas

    IPC: C07K16/28 ,  C07K16/30

    CPC classification number: C07K16/2809 ,  C07K16/2863 ,  C07K16/3069 ,  C07K2317/31 ,  C07K2317/55

    Abstract: The present invention provides antibodies that bind to CD3 with weak or no detectable binding affinity and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with low affinity and induce human T cell proliferation and hence induce T cell-mediated killing of tumor cells with high efficacy. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3 with weak or no detectable binding affinity in an in vitro assay, and a second antigen-binding molecule that specifically binds human tumor-associated antigen. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing target antigen, such as PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers or other diseases where immunotherapy, i.e . effector cell immunomodulation is warranted.

    Abstract translation: 本发明提供与CD3结合弱或不可检测的结合亲和力的抗体及其使用方法。 根据某些实施方案，本发明的抗体以低亲和力结合人CD3，并诱导人T细胞增殖，因此以高效力诱导T细胞介导的杀伤肿瘤细胞。 根据某些实施方案，本发明提供双特异性抗原结合分子，其包含在体外测定中特异性结合人CD3或弱结合亲和力的第一抗原结合结构域，以及特异性结合人的第二抗原结合分子 肿瘤相关抗原。 在某些实施方案中，本发明的双特异性抗原结合分子能够抑制表达靶抗原（例如PSMA）的肿瘤的生长。 本发明的抗体和双特异性抗原结合分子可用于治疗其中期望和/或治疗有益的上调或诱导的靶向免疫应答的疾病和病症。 例如，本发明的抗体可用于治疗各种癌症或其它疾病，其中免疫疗法即效应细胞免疫调节是有必要的。

Patent Agency Ranking